Global Angiotensin II Receptor Blockers Market Size By Type (Azilsartan, Candesartan), By Application (Chronic Kidney Diseases, Heart Failure), By Region, And Segment Forecasts, 2023 to 2032

The Global Angiotensin II Receptor Blockers (ARBs) Market was valued at USD 9.8 billion in 2023 and is projected to reach USD 14.7 billion by 2031, growing at a CAGR of 5.2% during the forecast period from 2023 to 2031. The market's expansion is fueled by the rising prevalence of hypertension, cardiovascular diseases, and diabetic nephropathy, as well as the increasing geriatric population worldwide. ARBs are widely used in managing these conditions due to their efficacy and relatively fewer side effects compared to ACE inhibitors. Continued clinical trials and the introduction of combination therapies are expected to further drive market growth.

Drivers:

1. Increasing Prevalence of Hypertension and Cardiovascular Disorders:

Hypertension remains one of the most prevalent chronic conditions globally. ARBs are a first-line treatment, especially in patients intolerant to ACE inhibitors. Their role in reducing cardiovascular risk has made them integral to clinical practice.

2. Growing Aging Population:

The global elderly demographic is expanding, particularly in developed regions. Older individuals are more susceptible to heart-related conditions, boosting the demand for effective antihypertensive therapies like ARBs.

3. Rising Adoption of Combination Therapies:

Fixed-dose combinations of ARBs with other antihypertensive agents such as diuretics or calcium channel blockers are gaining traction due to improved patient compliance and enhanced therapeutic efficacy.

Restraints:

1. Patent Expiry and Generic Competition:

Several key ARBs, including losartan and valsartan, have lost patent protection, paving the way for generics. While this increases accessibility, it also leads to reduced profit margins for branded drug manufacturers.

2. Side Effects and Regulatory Concerns:

Despite being safer than many alternatives, ARBs have been associated with adverse effects such as hyperkalemia and kidney dysfunction in some patients, leading to cautious usage in high-risk groups.

Opportunity:

1. Untapped Markets in Emerging Economies:

Rising healthcare expenditure and increasing awareness in countries such as India, China, and Brazil offer lucrative growth opportunities. Government initiatives and improved access to healthcare are facilitating higher diagnosis and treatment rates.

2. Advancements in Personalized Medicine:

Pharmacogenomic research is enabling personalized dosing and selection of ARBs, which enhances patient outcomes and reduces adverse reactions. This represents a key innovation frontier in the ARB market.

Market by System Type Insights:

Based on drug type, Valsartan held the largest market share in 2023 due to its widespread use and established efficacy profile. However, the Olmesartan segment is expected to witness the fastest growth, driven by increasing clinical evidence supporting its superior blood pressure control and favorable safety profile in long-term use.

Market by End-use Insights:

Hospital Pharmacies accounted for the largest share in 2023, attributed to the high volume of prescriptions for ARBs initiated during inpatient care. Retail Pharmacies are expected to grow rapidly, supported by the rising trend of outpatient management of chronic conditions and improved accessibility to prescription drugs.

Market by Regional Insights:

North America dominated the global ARBs market in 2023 due to the high burden of hypertension, a well-established healthcare system, and the early adoption of advanced therapeutics. Meanwhile, the Asia-Pacific region is poised for the fastest growth during the forecast period, with increased disease awareness, expanding insurance coverage, and growing pharmaceutical manufacturing capabilities.

Competitive Scenario:

Leading companies in the Global Angiotensin II Receptor Blockers Market include:

Novartis AG

AstraZeneca PLC

Merck & Co., Inc.

Sanofi S.A.

Pfizer Inc.

Daiichi Sankyo Company, Limited

Bayer AG

Bristol-Myers Squibb

Teva Pharmaceutical Industries Ltd.

These companies are engaged in strategic collaborations, new product launches, and expansion in emerging markets to strengthen their competitive position.

Scope of Work – Global Angiotensin II Receptor Blockers Market

Report Metric Details

Market Size (2023) USD 9.8 Billion

Projected Market Size (2031) USD 14.7 Billion

CAGR (2023–2031) 5.2%

Market Segments By Drug Type (Losartan, Valsartan, Irbesartan, etc.), By End-use (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Growth Drivers Rising prevalence of hypertension, aging population, and adoption of combination therapies

Opportunities Personalized medicine, untapped emerging markets

Key Market Developments:

2023: Novartis expanded its cardiovascular portfolio with extended-release ARB combination therapies aimed at improving patient compliance.

2024: AstraZeneca entered a licensing agreement with a biotech firm to develop next-generation ARB molecules with enhanced receptor selectivity.

2025: Teva launched a cost-effective generic version of irbesartan in emerging markets to expand access to affordable hypertension treatments.

FAQs:

1) What is the current market size of the Global Angiotensin II Receptor Blockers Market?

The market was valued at USD 9.8 billion in 2023.

2) What is the major growth driver of the Global Angiotensin II Receptor Blockers Market?

The increasing prevalence of hypertension and cardiovascular diseases is the major growth driver.

3) Which is the largest region during the forecast period in the Global Angiotensin II Receptor Blockers Market?

North America is expected to remain the largest region throughout the forecast period.

4) Which segment accounted for the largest market share in the Global Angiotensin II Receptor Blockers Market?

The Valsartan drug type segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Angiotensin II Receptor Blockers Market?

Key players include Novartis AG, AstraZeneca, Merck & Co., Sanofi, Pfizer, and Teva Pharmaceutical Industries.

Let me know if you'd like this in a Word document or formatted for a presentation!